Entero Therapeutics's common stock is $610.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company). Positive growth indicates new issuance/dilution; negative growth indicates reductions/buybacks.
As of the most recent data (March 2026), ENTO shows a common stock of $610. That compares with $480 in the prior-year period — up 28.1% year over year. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, ENTO's common stock is now $610 (was $480) — a 28.1% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Entero Therapeutics is outperforming or lagging.
Tracking ENTO's common stock over time shows whether Entero Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $610 That compares with $480 in the prior-year period — up 28.1% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this common stock page, Stockcircle has Entero Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect common stock (currently $610) with ownership activity and broader fundamentals.